English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

BACKGROUND Anaplastic meningioma (AM) is a rare and aggressive intracranial tumor with very limited treatment options. TTFields is an established therapy and indicated for the treatment of newly diagnosed and recurrent glioblastoma (GBM) patients. The phase 3 study METIS tests the application in another intracranial cancer type, more specifically brain metastases of non-small cell lung cancer. First preclinical data show that TTFields can reduce proliferation of patient-derived meningioma cells and one first case report of a GBM patient with an in-field meningioma was published. First clinical trials are underway to investigate the safety and efficacy in meningioma patients (NCT02847559). Here, we describe first surveillance data on anaplastic meningioma patients treated with the TTFields device indicated for GBM treatment. METHODS Global post-market surveillance data of patients with anaplastic meningioma were assessed employing the MedDRA body system (System organ class (SOC) and preferred terms) with data cut-off in April 2020. RESULTS A total of 29 patients with AM were treated since 2015 to date. The median age is 57y (range 26-74y; based on YOB). Of those 9 (31%) were female and 20 (69%) were male. 15 (52 %) patients with AM reported at least one adverse event (AE). A total of 51 AEs were reported, of those 32 were assessed by the manufacturer as potentially related to TTFields treatment. Most commonly reported were skin reactions beneath the transducer arrays (n=15). No serious adverse events related to TTFields were reported. CONCLUSION Here we present the first post-market surveillance data of anaplastic meningioma patients treated with TTFields. Clinical studies are warranted to investigate the safety and efficacy for the use of TTFields in anaplastic meningioma patients.

CTNI-59. FIRST SAFETY ANALYSIS OF ANAPLASTIC MENINGIOMA PATIENTS TREATED WITH TUMOR TREATING FIELDS (TTFIELDS)